Evidence map›Paper›PMID 24941932›Full record

ReviewDer Urologe. Ausg. A2014

[Focal therapy for prostate cancer in Germany - 2014 status].

A Roosen, R Ganzer, B Hadaschik, J Köllermann, A Blana, T Henkel, A-B Liehr, D Baumunk, S Machtens, G Salomon and 5 more

Erratum issuedAbstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Der Urologe. Ausg. A, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

15 authors at 10 institutions in 1 country.

A RoosenUrologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Klinikum Großhadern, Marchioninistraße 15, 81377, München, Deutschland, alexander.roosen@med.uni-muenchen.de.
R Ganzer
B Hadaschik
J Köllermann
A Blana
T Henkel
A-B Liehr
D Baumunk
S Machtens
G Salomon
L Sentker
U Witsch
K U Köhrmann
M Schostak
Arbeitskreis für Fokale und Mikrotherapie der Akademie der Deutschen Gesellschaft für Urologie e.V
Klinikum Magdeburg · DEHeidelberg University · DEMartini-Klinik · DEUniversität Hamburg · DEInstitut für Hämatopathologie Hamburg · DEKlinikum Fürth · DEKrankenhaus Nordwest · DELMU Klinikum · DELudwig-Maximilians-Universität München · DEPraxis für Humangenetik · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn localized low-risk prostate cancer (PCa), there is a therapeutic dilemma between possible overtreatment by one of the standard therapies and potentially insufficient cancer control by active surveillance (AS). Focal therapy (FT) provides an alternative therapeutic option as it aims to preserve the organ and to eliminate the cancer focus at the same time.

methodsIn this article the current state of FT for localized low-risk prostate carcinoma in Germany is described. In addition, criteria that should be used to select patients for FT are proposed.

resultsCurrently, the effectiveness of FT is under evaluation by two multicenter, prospective studies in Germany: TOOKAD and HEMI. However, localized low-risk prostate carcinoma remains a diagnostic challenge: Multiparametric MRI as well as histopathological second opinion are considered mandatory in addition to transrectal biospy.

conclusionThe oncological outcome of both the TOOKAD and HEMI study will be crucial for any form of FT for prostate carcinoma in Germany in the future. However, there is a remarkably high acceptance of FT among patients.

Indexed as

Evidence-Based MedicineGermanyHumansMaleMinimally Invasive Surgical ProceduresOrgan Sparing TreatmentsPrognosisProstatectomyProstatic NeoplasmsRadiotherapy, ConformalRisk AssessmentTreatment OutcomeWatchful Waiting

Identifiers

PMID24941932
OpenAlexW79243042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.